TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2892047

Group type: EXPERIMENTAL
Intervention: Calcium 500 mg plus intranasal salmon calcitonin 50 IU/day for 5 days per week
Number of subjects: 79

Group type: COMPARATOR
Intervention: Calcium 500 mg/day
Number of subjects: 79
Study: 28882741

Group type: EXPERIMENTAL
Intervention: Positive pressure (PP)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Suctioning (SUC)
Number of subjects: 69
Study: 25766052

Group type: EXPERIMENTAL
Intervention: Static hamstring stretching (4 exercises, 30 seconds each, performed twice with 15 seconds rest, 6 days per week for 7 weeks)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Static hamstring stretching
Number of subjects: 103

Group type: COMPARATOR
Intervention: Control group (no stretching)
Number of subjects: 103
Study: 25613431

Group type: EXPERIMENTAL
Intervention: Losartan 100 mg
Number of subjects: 117

Group type: COMPARATOR
Intervention: No losartan
Number of subjects: 117
Study: 23622915

Group type: EXPERIMENTAL
Intervention: Essential medical therapy before PCI
Number of subjects: 60386

Group type: EXPERIMENTAL
Intervention: Essential medical therapy at discharge after PCI
Number of subjects: 60386

Group type: EXPERIMENTAL
Intervention: Aspirin use before PCI
Number of subjects: 60386

Group type: EXPERIMENTAL
Intervention: Aspirin use after PCI
Number of subjects: 60386

Group type: EXPERIMENTAL
Intervention: Statin use before PCI
Number of subjects: 60386

Group type: EXPERIMENTAL
Intervention: Statin use after PCI
Number of subjects: 60386

Group type: EXPERIMENTAL
Intervention: β-Blocker use before PCI
Number of subjects: 60386

Group type: EXPERIMENTAL
Intervention: Clopidogrel use after PCI
Number of subjects: 60386

Group type: EXPERIMENTAL
Intervention: Medical therapy comparison based on history of myocardial infarction or revascularization before PCI
Number of subjects: 60386

Group type: EXPERIMENTAL
Intervention: Statin therapy likelihood based on gender and dialysis status
Number of subjects: 60386
Study: 20564933

Group type: EXPERIMENTAL
Intervention: Propofol (4 mg/kg/hr) + Ketamine (2 mg/kg/hr)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Propofol (4 mg/kg/hr) + Fentanyl (3 microg/kg/hr)
Number of subjects: 0
Study: 18230942

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Structured Writing Therapy (SWT)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Waitlist Control
Number of subjects: 125
Study: 20675425

Group type: EXPERIMENTAL
Intervention: NovaMin powder with NovaMin‐containing toothpaste (group 1)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Placebo powder with NovaMin‐containing toothpaste (group 2)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo powder with desensitizing toothpaste containing potassium nitrate (group 3)
Number of subjects: 60
Study: 16390769

Group type: EXPERIMENTAL
Intervention: Tibolone
Number of subjects: 156

Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 156
Study: 11135090

Group type: EXPERIMENTAL
Intervention: New PD fluid
Number of subjects: 80

Group type: COMPARATOR
Intervention: Conventional PD fluid
Number of subjects: 80
Study: 9587114

Group type: EXPERIMENTAL
Intervention: Telomerase activity in hepatocellular carcinoma (HCC)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Telomerase activity in cirrhotic liver samples
Number of subjects: 44

Group type: COMPARATOR
Intervention: Telomerase activity in large noncancerous nodules
Number of subjects: 44

Group type: COMPARATOR
Intervention: Telomerase activity in large regenerative nodules
Number of subjects: 44
Study: 7785204

Group type: EXPERIMENTAL
Intervention: Enhanced physical training
Number of subjects: 134

Group type: COMPARATOR
Intervention: Traditional rehabilitation (controls)
Number of subjects: 134
Study: 2457523

Group type: EXPERIMENTAL
Intervention: Flurbiprofen
Number of subjects: 56

Group type: COMPARATOR
Intervention: Naproxen
Number of subjects: 56

Group type: COMPARATOR
Intervention: Indomethacin
Number of subjects: 56
Study: 31146028

Group type: EXPERIMENTAL
Intervention: Computer-based simulator training of spatial skills
Number of subjects: 41

Group type: COMPARATOR
Intervention: Neutral activity (control group)
Number of subjects: 41
Study: 30666799

Group type: EXPERIMENTAL
Intervention: Anlotinib
Number of subjects: 294

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 294
Study: 28910811

Group type: EXPERIMENTAL
Intervention: Aerobic exercise training for 12 weeks
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 39
Study: 26948519

Group type: EXPERIMENTAL
Intervention: Ginger (500 mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 25188700

Group type: EXPERIMENTAL
Intervention: TAU+EMDR
Number of subjects: 12

Group type: COMPARATOR
Intervention: TAU
Number of subjects: 12
Study: 22038079

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 813

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 813
Study: 18204981

Group type: EXPERIMENTAL
Intervention: alteplase infusion plus weight-adjusted UH (24-48 h) and then enoxaparin (7 days)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: enoxaparin
Number of subjects: 80

Group type: COMPARATOR
Intervention: UH standard regimen
Number of subjects: 80
Study: 17688686

Group type: EXPERIMENTAL
Intervention: O. niloticus (larvivorous fish) introduced into treated ponds
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control pond (untreated)
Number of subjects: 0
Study: 15506870

Group type: EXPERIMENTAL
Intervention: Work sharing policy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fixed assignment policy
Number of subjects: 0
Study: 11513446

Group type: EXPERIMENTAL
Intervention: Midodrine (5 mg three times a day, increased to 15 mg three times a day as needed)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Fluid therapy (increased fluid intake, salt tablets, and counseling)
Number of subjects: 61
Study: 9591742

Group type: EXPERIMENTAL
Intervention: High-stearic acid diet
Number of subjects: 15

Group type: COMPARATOR
Intervention: High-oleic acid diet
Number of subjects: 15
Study: 7839092

Group type: EXPERIMENTAL
Intervention: Triple treatment consisting of bismuth subnitrate, oxytetracycline, and metronidazole for 14 days
Number of subjects: 74
Study: 3279095

Group type: EXPERIMENTAL
Intervention: Ketotifen
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 29768465

Group type: EXPERIMENTAL
Intervention: Truncated treatment (stopping antibiotics at Day 7)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Continued treatment (continuing antibiotics until Day 14)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Truncated treatment
Number of subjects: 54

Group type: COMPARATOR
Intervention: Continued treatment
Number of subjects: 54
Study: 25932993

Group type: EXPERIMENTAL
Intervention: Negative pressure wound therapy (NPWT)
Number of subjects: 20
Study: 25047457

Group type: EXPERIMENTAL
Intervention: PS post/cam tibial insert
Number of subjects: 111

Group type: COMPARATOR
Intervention: CS anterior‐lipped tibial insert
Number of subjects: 111
Study: 22640986

Group type: EXPERIMENTAL
Intervention: Ezetimibe (10mg/day)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Pravastatin (10mg/day)
Number of subjects: 19
Study: 20863930

Group type: EXPERIMENTAL
Intervention: Ropivacaine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Bupivacaine
Number of subjects: 40
Study: 18826867

Group type: EXPERIMENTAL
Intervention: Different methods for average bioequivalence evaluation including widening bioequivalence limits, scaling limits, and alternative bioavailability measures.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Methods to establish bioequivalence limits combined with alternative methods for constructing confidence intervals.
Number of subjects: 0
Study: 16011671

Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg twice daily
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg twice daily
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg once daily
Number of subjects: 45

Group type: COMPARATOR
Intervention: Lansoprazole 30 mg once daily
Number of subjects: 45
Study: 12385455

Group type: EXPERIMENTAL
Intervention: Sedation procedure
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Lesion identification/removal
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Demographic data
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Patient history
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Procedure quality
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Procedure interpretation
Number of subjects: 122
Study: 10437376

Group type: EXPERIMENTAL
Intervention: Vagus nerve stimulation (VNS)
Number of subjects: 0
Study: 8574510

Group type: EXPERIMENTAL
Intervention: BAY x 7195, 50 mg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: BAY x 7195, 100 mg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: BAY x 7195, 250 mg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: BAY x 7195, 500 mg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: BAY x 7195, 1000 mg
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 11527144

Group type: EXPERIMENTAL
Intervention: 10 mg of bisoprolol once daily (o.d., n = 20)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 20 mg of nifedipine sustained release (SR) b.i.d. (n = 20)
Number of subjects: 40
Study: 334688

Group type: EXPERIMENTAL
Intervention: Bromperidol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 0
Study: 29168881

Group type: EXPERIMENTAL
Intervention: Early closure of a temporary ileostomy (at 8-13 days)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Late closure of a temporary ileostomy (at more than 12 weeks)
Number of subjects: 112
Study: 27595692

Group type: EXPERIMENTAL
Intervention: Automated hovering intervention based on behavioral economics concepts, implemented over 1 year.
Number of subjects: 1509

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 1509
Study: 25044050

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (24 IU)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 22914037

Group type: EXPERIMENTAL
Intervention: Biocellulose dressing with polyhexanide (Group A)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Hydrophobic dressing with dialkyl-carbamoyl-chloride (Group B)
Number of subjects: 60
Study: 20938333

Group type: EXPERIMENTAL
Intervention: Oral pregabalin 150 mg/12 h
Number of subjects: 48

Group type: COMPARATOR
Intervention: Prazepam 10 mg/12 h
Number of subjects: 48
Study: 18269558

Group type: EXPERIMENTAL
Intervention: Left Ventricular (LV) pacing
Number of subjects: 22

Group type: COMPARATOR
Intervention: Biventricular (BIV) pacing
Number of subjects: 22
Study: 16187778

Group type: COMPARATOR
Intervention: Bupropion
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Tobacco Abstinence
Number of subjects: 53
Study: 12944569

Group type: EXPERIMENTAL
Intervention: Structured treatment interruption for four months followed by a change in antiretroviral regimen
Number of subjects: 270

Group type: COMPARATOR
Intervention: Immediate change in regimen (control group)
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Structured treatment interruption
Number of subjects: 270

Group type: COMPARATOR
Intervention: Structured treatment interruption and immediate change in regimen
Number of subjects: 270
Study: 10658043

Group type: EXPERIMENTAL
Intervention: Acetazolamide (Acz; 10 mg/kg body wt iv)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Control (Con)
Number of subjects: 7
Study: 9074366

Group type: EXPERIMENTAL
Intervention: Early necrosectomy (within 48 to 72 hours of onset)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Late necrosectomy (at least 12 days after onset)
Number of subjects: 36
Study: 8436155

Group type: EXPERIMENTAL
Intervention: Cimetidine 400 mg orally three times a day
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study: 3094804

Group type: EXPERIMENTAL
Intervention: Hypnotherapy (6 weeks)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (17 patients with low susceptibility)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (10 patients with low susceptibility)
Number of subjects: 39
Study: 28898530

Group type: EXPERIMENTAL
Intervention: Intradiscal electrothermal therapy (IDET)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Circumferential lumbar fusion with femoral ring allograft (FRA)
Number of subjects: 122
Study: 26199198

Group type: EXPERIMENTAL
Intervention: Solifenacin 5 mg
Number of subjects: 547

Group type: EXPERIMENTAL
Intervention: Solifenacin 10 mg
Number of subjects: 547

Group type: EXPERIMENTAL
Intervention: Pooled Solifenacin
Number of subjects: 547

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 547
Study: 24754203

Group type: EXPERIMENTAL
Intervention: Training group (TG)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 55
Study: 22411483

Group type: EXPERIMENTAL
Intervention: Clonidine 150 μg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Midazolam 7.5 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Clonidine 150 μg and Midazolam 7.5 mg
Number of subjects: 10
Study: 20973267

Group type: EXPERIMENTAL
Intervention: Canfosfamide + PLD (1000 mg/m² canfosfamide and 50 mg/m² PLD)
Number of subjects: 125

Group type: COMPARATOR
Intervention: PLD alone (50 mg/m²)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Canfosfamide + PLD
Number of subjects: 125

Group type: COMPARATOR
Intervention: PLD alone
Number of subjects: 125
Study: 18926983

Group type: EXPERIMENTAL
Intervention: Describing their actions in detail
Number of subjects: 2

Group type: COMPARATOR
Intervention: Performing an irrelevant verbal task
Number of subjects: 2
Study: 15809515

Group type: EXPERIMENTAL
Intervention: Chronic hydrocortisone treatment (40 mg daily for 1 week)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Acute hydrocortisone treatment (40 mg)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 11435251

Group type: EXPERIMENTAL
Intervention: Positive end-expiratory pressure (PEEP) at various levels (5, 10, 15, 20 cm H2O) and tidal volume (VT) with plateau pressures of 10, 15, 20, 30, 35, and 45 cm H2O.
Number of subjects: 5
Study: 9550542

Group type: EXPERIMENTAL
Intervention: Postmenopausal women
Number of subjects: 138

Group type: COMPARATOR
Intervention: Premenopausal women
Number of subjects: 138
Study: 8001714

Group type: EXPERIMENTAL
Intervention: Medical records
Number of subjects: 2917

Group type: EXPERIMENTAL
Intervention: USL registers
Number of subjects: 2917

Group type: EXPERIMENTAL
Intervention: Prescriptions
Number of subjects: 2917

Group type: EXPERIMENTAL
Intervention: Combined sources
Number of subjects: 2917

Group type: COMPARATOR
Intervention: Family doctors' conclusions
Number of subjects: 2917
Study: 2839382

Group type: EXPERIMENTAL
Intervention: Oil-soluble contrast medium
Number of subjects: 175

Group type: COMPARATOR
Intervention: Aqueous contrast medium
Number of subjects: 175
Study: 8512477

Group type: EXPERIMENTAL
Intervention: Intravenous methylprednisolone sodium succinate (250 mg every 6 hours for 3 days) followed by oral prednisone (1 mg/kg per day for 11 days)
Number of subjects: 457

Group type: EXPERIMENTAL
Intervention: Oral prednisone (1 mg/kg per day for 14 days)
Number of subjects: 457

Group type: COMPARATOR
Intervention: Placebo (oral for 14 days)
Number of subjects: 457
Study: 677577

Group type: EXPERIMENTAL
Intervention: Phleborheography
Number of subjects: 75
Study: 31106353

Group type: EXPERIMENTAL
Intervention: 4 weeks of systemic, pathogen-targeted antibiotic therapy
Number of subjects: 123

Group type: COMPARATOR
Intervention: 6 weeks of systemic, pathogen-targeted antibiotic therapy
Number of subjects: 123
Study: 28277112

Group type: EXPERIMENTAL
Intervention: 4g MYO and 400μg folic acid before and during ovulation induction (Group 1)
Number of subjects: 196

Group type: COMPARATOR
Intervention: Recombinant FSH and 400μg folic acid (Group 2)
Number of subjects: 196
Study: 26267623

Group type: EXPERIMENTAL
Intervention: Open monitoring with fetal ST-segment analysis
Number of subjects: 11108

Group type: COMPARATOR
Intervention: Masked monitoring (normal fetal heart-rate monitor)
Number of subjects: 11108
Study: 24009749

Group type: EXPERIMENTAL
Intervention: 10 mg lutein supplement
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 21114552

Group type: EXPERIMENTAL
Intervention: Weekly e-mail messages and monthly personal e-mail messages with reporting of weight (n = 28)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control group (n = 27)
Number of subjects: 55
Study: 19017419

Group type: EXPERIMENTAL
Intervention: Panax ginseng (G115)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Panax ginseng (Cheong Kwan Jang)
Number of subjects: 29
Study: 17259481

Group type: EXPERIMENTAL
Intervention: Insulin glargine
Number of subjects: 217

Group type: COMPARATOR
Intervention: Rosiglitazone
Number of subjects: 217
Study: 15234035

Group type: EXPERIMENTAL
Intervention: RT plus cisplatin
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: RT plus carboplatin
Number of subjects: 101

Group type: COMPARATOR
Intervention: RT alone
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: TGTV <22.8 cm(3)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: TGTV >22.8 cm(3)
Number of subjects: 101
Study: 11412291

Group type: EXPERIMENTAL
Intervention: Propofol 2.5 mg kg(‐1)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Propofol 3.0 mg kg(‐1)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Propofol 3.5 mg kg(‐1)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Fentanyl 3.0 microg kg(‐1)
Number of subjects: 60
Study: 9764960

Group type: EXPERIMENTAL
Intervention: Formulation I
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Formulation II
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Formulation III
Number of subjects: 18

Group type: COMPARATOR
Intervention: Reference capsule
Number of subjects: 18
Study: 8001064

Group type: EXPERIMENTAL
Intervention: 0.42% F gel once a day for 1 year
Number of subjects: 55

Group type: COMPARATOR
Intervention: 1.23% F gel for 4 weeks followed by 0.42% F gel daily for 1 year
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Unstimulated saliva flow < 0.1 ml/min
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Stimulated salivary flow < 0.5 ml/min
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Unstimulated saliva flow > 0.1 ml/min with 0.42% F gel
Number of subjects: 55
Study: 3356120

Group type: EXPERIMENTAL
Intervention: ketoconazole 200 mg administered after a fast (Treatment A)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: ketoconazole 200 mg with a standardized high-fat meal (Treatment B)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: ketoconazole 200 mg with a standardized high-carbohydrate meal (Treatment C)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: ketoconazole 200 mg after pretreatment with glutamic acid hydrochloride 680 mg (Treatment D)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: ketoconazole 200 mg in a simulated achlorhydric state (Treatment E)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: ketoconazole 200 mg with glutamic acid hydrochloride in a simulated achlorhydric state (Treatment F)
Number of subjects: 12
Study: 29703518

Group type: EXPERIMENTAL
Intervention: Atrial fibrillation (AF) population
Number of subjects: 7500

Group type: EXPERIMENTAL
Intervention: Anticoagulated patients
Number of subjects: 7500
Study: 29229052

Group type: EXPERIMENTAL
Intervention: Thrust Manipulation (TM)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Sham Manipulation (SM)
Number of subjects: 24
Study: 25956366

Group type: EXPERIMENTAL
Intervention: Laparoscopic vaginoplasty using a single peritoneal flap (SPF)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Healthy women (control group)
Number of subjects: 83
Study: 23249605

Group type: EXPERIMENTAL
Intervention: Single-session EUS-ERCP (group A)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: EUS and ERCP in different sessions (group B)
Number of subjects: 180

Group type: COMPARATOR
Intervention: ERCP-only procedure (group C)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: All groups (A, B, C)
Number of subjects: 180
Study: 21452051

Group type: EXPERIMENTAL
Intervention: LifeWindows intervention
Number of subjects: 594

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 594
Study: 19195133

Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave lithotripsy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Emergency extracorporeal shock wave lithotripsy service
Number of subjects: 0
Study: 17333040

Group type: EXPERIMENTAL
Intervention: Tonsillotomy
Number of subjects: 59

Group type: COMPARATOR
Intervention: Tonsillectomy
Number of subjects: 59
Study: 14769704

Group type: EXPERIMENTAL
Intervention: Roxithromycin therapy for 30 days
Number of subjects: 272

Group type: COMPARATOR
Intervention: No antibiotic therapy (control group)
Number of subjects: 272

Group type: COMPARATOR
Intervention: Both groups (Roxithromycin and control)
Number of subjects: 272
Study: 11290877

Group type: EXPERIMENTAL
Intervention: Lanepitant 50 mg daily
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Lanepitant 100 mg daily
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Lanepitant 200 mg twice daily
Number of subjects: 93

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study: 9716766

Group type: EXPERIMENTAL
Intervention: Laparoscopic resection
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional resection
Number of subjects: 60
Study: 7803735

Group type: EXPERIMENTAL
Intervention: Doxacurium (DOX) 80 micrograms/kg
Number of subjects: 75

Group type: COMPARATOR
Intervention: High-dose vecuronium (VEC) 400 micrograms/kg
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Doxacurium (DOX) in DOX-70 group
Number of subjects: 75

Group type: COMPARATOR
Intervention: High-dose vecuronium (VEC)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Doxacurium (DOX) and High-dose vecuronium (VEC)
Number of subjects: 75
Study: 2904371

Group type: EXPERIMENTAL
Intervention: 10 mg sublingual tablet formulation of temazepam
Number of subjects: 10

Group type: COMPARATOR
Intervention: 10 mg oral capsule formulation of temazepam
Number of subjects: 10